A combined panel of salivary biomarkers in de novo Parkinson's Disease.

Our study proposes a novel biomarker panel using saliva, a non-invasive biofluid, in de novo PD patients, with implications in understanding the molecular pathways involved in PD pathogenesis and the relevance of different molecular pathways in determining clinical PD subtypes. This article is protected by copyright. All rights reserved.